Linked Life Data

19756950

Source:http://linkedlifedata.com/resource/pubmed/id/19756950

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
6
pubmed:dateCreated
2010-1-21
pubmed:abstractText
Direct thrombin inhibitors (DTIs) are a class of anticoagulants that bind selectively to thrombin and block its interaction with its substrates. Dabigatran etexilate and AZD0837, the new generation of DTIs, are now under intense development, and are potentially of great interest for internists. Dabigatran etexilate is a potent, non-peptidic small molecule that specifically and reversibly inhibits both free and clot-bound thrombin by binding to the active site of thrombin molecule. It has been already licensed in the European Union and in Canada for the prevention of VTE in patients undergoing hip- and knee-replacement surgery. Ongoing trials are evaluating its efficacy and safety for the treatment of deep venous thrombosis and pulmonary embolism, primary and secondary prevention of VTE, prevention of systemic embolism in patients with non-valvular atrial fibrillation, and prevention of cardiac events in patients with acute coronary syndromes. AZD0837 is the prodrug of ARH06737, a potent, competitive, reversible inhibitor of free and fibrin-bound thrombin. At present, only limited, preclinical, phase I and phase II clinical data have been presented. The drug has now entered a phase III clinical program in the population of patients with atrial fibrillation. Their properties and the oral administration render these compounds, theoretically, more convenient than both vitamin K antagonist and low molecular weight heparins. However, only reports from clinical practice patterns over the next months and years will tell us how and when to use the new DTIs.
pubmed:commentsCorrections
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Dec
pubmed:issn
1970-9366
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
4
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
479-84
pubmed:meshHeading
pubmed:year
2009
pubmed:articleTitle
New direct thrombin inhibitors.
pubmed:affiliation
Department of Clinical Medicine, University of Insubria, Varese, Italy. alexsquizzo@libero.it
pubmed:publicationType
Journal Article